A Multicentre, Open-label, Single-arm, Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Jun 2019
Price : $35 *
At a glance
- Drugs Osimertinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Pharmacodynamics; Pharmacogenomic; Registrational
- Acronyms ELIOS
- Sponsors AstraZeneca
- 29 May 2019 Status changed from recruiting to active, no longer recruiting.
- 12 Mar 2019 Planned End Date changed from 14 Nov 2022 to 16 Oct 2022.
- 08 Feb 2019 Planned number of patients changed from 100 to 150.